Tech Company Financing Transactions
REGENXBIO Funding Round
Brookside Capital and Venrock participated in a $30 million Series C venture round for REGENXBIO. The round closed on 1/22/2015.
Transaction Overview
Company Name
Announced On
1/22/2015
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Brookside Capital (Lead Investor)
Venrock (Lead Investor) (Camille Samuels)
Proceeds Purpose
REGENXBIO plans to use the proceeds to advance its lead programs through clinical development, build out its clinical and manufacturing infrastructure, and expand its team.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9600 Blackwell Rd. 210
Rockville, MD 20850
USA
Rockville, MD 20850
USA
Phone
Website
Email Address
Not Recorded
Overview
REGENXBIO (NASDAQ: RGNX) is leveraging our proprietary NAV Technology to advance the development of life-changing adeno-associated viral (AAV) gene therapy treatments for lysosomal storage disorders and ocular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ken Mills
Chief Financial Officer
Vit Vasista
Chief Medical Officer
Stephen Yoo
Chief Scientific Officer
Olivier Danos
Chief Technical Officer
Curran Simpson
VP - General Counsel
Patrick Christmas
VP - Human Resources
Shiva Fritsch
VP - Operations
Ram Palanki
Browse more venture capital transactions:
Prev: 1/22/2015: Selvera venture capital transaction
Next: 1/22/2015: XOR Data Exchange venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs